Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Nov 16;161(10):1281–1286.

Drug interactions and the statins

R J Herman 1
PMCID: PMC1230792  PMID: 10584091

Abstract

Drug interactions commonly occur in patients receiving treatment with multiple medications. Most interactions remain unrecognized because drugs, in general, have a wide margin of safety or because the extent of change in drug levels is small when compared with the variation normally seen in clinical therapy. All drug interactions have a pharmacokinetic or pharmacodynamic basis and are predictable given an understanding of the pharmacology of the drugs involved. Drugs most liable to pose problems are those having concentration-dependent toxicity within, or close to, the therapeutic range; those with steep dose-response curves; those having high first-pass metabolism or those with a single, inhibitable route of elimination. Knowing which drugs possess these intrinsic characteristics, together with a knowledge of hepatic P-450 metabolism and common enzyme-inducing and enzyme-inhibiting drugs, can greatly assist physicians in predicting interactions that may be clinically relevant. This article reviews the pharmacology of drug interactions that can occur with hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) to illustrate the scope of the problem and the ways in which physicians may manage this important therapeutic class of drugs.

Full Text

The Full Text of this article is available as a PDF (225.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdul-Ghaffar N. U., el-Sonbaty M. R. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol. 1995 Dec;21(4):340–341. doi: 10.1097/00004836-199512000-00027. [DOI] [PubMed] [Google Scholar]
  2. Ahmad S. Diltiazem myopathy. Am Heart J. 1993 Dec;126(6):1494–1495. doi: 10.1016/0002-8703(93)90572-q. [DOI] [PubMed] [Google Scholar]
  3. Azie N. E., Brater D. C., Becker P. A., Jones D. R., Hall S. D. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998 Oct;64(4):369–377. doi: 10.1016/S0009-9236(98)90067-4. [DOI] [PubMed] [Google Scholar]
  4. Ballantyne C. M., Bourge R. C., Domalik L. J., Eisen H. J., Fishbein D. P., Kubo S. H., Lake K. D., Radovancevic B., Taylor D. O., Ventura H. O. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol. 1996 Sep 1;78(5):532–535. doi: 10.1016/s0002-9149(96)00358-x. [DOI] [PubMed] [Google Scholar]
  5. Bertz R. J., Granneman G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997 Mar;32(3):210–258. doi: 10.2165/00003088-199732030-00004. [DOI] [PubMed] [Google Scholar]
  6. Boberg M., Angerbauer R., Fey P., Kanhai W. K., Karl W., Kern A., Ploschke J., Radtke M. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos. 1997 Mar;25(3):321–331. [PubMed] [Google Scholar]
  7. Bradford R. H., Shear C. L., Chremos A. N., Dujovne C. A., Franklin F. A., Grillo R. B., Higgins J., Langendorfer A., Nash D. T., Pool J. L. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994 Oct 1;74(7):667–673. doi: 10.1016/0002-9149(94)90307-7. [DOI] [PubMed] [Google Scholar]
  8. Cupp M. J., Tracy T. S. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998 Jan 1;57(1):107–116. [PubMed] [Google Scholar]
  9. Davidson M. H., Stein E. A., Dujovne C. A., Hunninghake D. B., Weiss S. R., Knopp R. H., Illingworth D. R., Mitchel Y. B., Melino M. R., Zupkis R. V. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997 Jan 1;79(1):38–42. doi: 10.1016/s0002-9149(96)00742-4. [DOI] [PubMed] [Google Scholar]
  10. Flint O. P., Masters B. A., Gregg R. E., Durham S. K. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997 Jul;145(1):99–110. doi: 10.1006/taap.1997.8174. [DOI] [PubMed] [Google Scholar]
  11. Fromm M. F., Kim R. B., Stein C. M., Wilkinson G. R., Roden D. M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999 Feb 2;99(4):552–557. doi: 10.1161/01.cir.99.4.552. [DOI] [PubMed] [Google Scholar]
  12. Gadbut A. P., Caruso A. P., Galper J. B. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 1995 Oct;27(10):2397–2402. doi: 10.1016/s0022-2828(95)92163-x. [DOI] [PubMed] [Google Scholar]
  13. Galiana J., Marchán E., Montés I., Pato S. Miopatías tóxicas en relación con la administración de hipolipidemiantes: son los fármacos los únicos responsables? Rev Clin Esp. 1995 Sep;195(9):620–622. [PubMed] [Google Scholar]
  14. Garnett W. R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995 Aug 1;52(15):1639–1645. doi: 10.1093/ajhp/52.15.1639. [DOI] [PubMed] [Google Scholar]
  15. Giordano N., Senesi M., Mattii G., Battisti E., Villanova M., Gennari C. Polymyositis associated with simvastatin. Lancet. 1997 May 31;349(9065):1600–1601. doi: 10.1016/S0140-6736(05)61628-5. [DOI] [PubMed] [Google Scholar]
  16. Grundy S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988 Jul 7;319(1):24–33. doi: 10.1056/NEJM198807073190105. [DOI] [PubMed] [Google Scholar]
  17. Haria M., McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs. 1997 Feb;53(2):299–336. doi: 10.2165/00003495-199753020-00008. [DOI] [PubMed] [Google Scholar]
  18. Herman R. J., Szakas C. B., Verbeeck R. K. Analysis of polymorphic variation in drug metabolism: II. Effects of data transformation on the sensitivity and specificity of modal detection. Clin Invest Med. 1994 Aug;17(4):290–296. [PubMed] [Google Scholar]
  19. Hino I., Akama H., Furuya T., Ueda H., Taniguchi A., Hara M., Kashiwazaki S. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum. 1996 Jul;39(7):1259–1260. doi: 10.1002/art.1780390730. [DOI] [PubMed] [Google Scholar]
  20. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol. 1996 Oct;132(10):1254–1254. doi: 10.1001/archderm.1996.03890340120028. [DOI] [PubMed] [Google Scholar]
  21. Hrab R. V., Hartman H. A., Cox R. H., Jr Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology. 1994 Jul;50(1):19–26. doi: 10.1002/tera.1420500104. [DOI] [PubMed] [Google Scholar]
  22. Hsu I., Spinler S. A., Johnson N. E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743–759. doi: 10.1177/106002809502907-818. [DOI] [PubMed] [Google Scholar]
  23. Hunt C. M., Westerkam W. R., Stave G. M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992 Jul 22;44(2):275–283. doi: 10.1016/0006-2952(92)90010-g. [DOI] [PubMed] [Google Scholar]
  24. Jacobsen W., Kirchner G., Hallensleben K., Mancinelli L., Deters M., Hackbarth I., Benet L. Z., Sewing K. F., Christians U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 Feb;27(2):173–179. [PubMed] [Google Scholar]
  25. Kantola T., Kivistö K. T., Neuvonen P. J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998 Jul;64(1):58–65. doi: 10.1016/S0009-9236(98)90023-6. [DOI] [PubMed] [Google Scholar]
  26. Kivistö K. T., Kantola T., Neuvonen P. J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998 Jul;46(1):49–53. doi: 10.1046/j.1365-2125.1998.00034.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kocarek T. A., Reddy A. B. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 1996 Nov;24(11):1197–1204. [PubMed] [Google Scholar]
  28. Lang J. E., Wang P., Glueck C. J. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clin Chim Acta. 1996 Oct 15;254(1):65–92. doi: 10.1016/0009-8981(96)06376-0. [DOI] [PubMed] [Google Scholar]
  29. Lea A. P., McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 1997 May;53(5):828–847. doi: 10.2165/00003495-199753050-00011. [DOI] [PubMed] [Google Scholar]
  30. Lees R. S., Lees A. M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995 Sep 7;333(10):664–665. doi: 10.1056/NEJM199509073331015. [DOI] [PubMed] [Google Scholar]
  31. Lennernäs H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997 May;32(5):403–425. doi: 10.2165/00003088-199732050-00005. [DOI] [PubMed] [Google Scholar]
  32. Mauro V. F. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993 Mar;24(3):195–202. doi: 10.2165/00003088-199324030-00002. [DOI] [PubMed] [Google Scholar]
  33. Michalets E. L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 Jan-Feb;18(1):84–112. [PubMed] [Google Scholar]
  34. Mück W., Ochmann K., Rohde G., Unger S., Kuhlmann J. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol. 1998 Feb;53(6):469–473. doi: 10.1007/s002280050408. [DOI] [PubMed] [Google Scholar]
  35. Mück W., Ritter W., Ochmann K., Unger S., Ahr G., Wingender W., Kuhlmann J. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther. 1997 Jun;35(6):255–260. [PubMed] [Google Scholar]
  36. Nakai A., Nishikata M., Uchida T., Ichikawa M., Matsuyama K. Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia. Biol Pharm Bull. 1997 Jan;20(1):104–106. doi: 10.1248/bpb.20.104. [DOI] [PubMed] [Google Scholar]
  37. Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996 Feb;6(1):1–42. doi: 10.1097/00008571-199602000-00002. [DOI] [PubMed] [Google Scholar]
  38. Neuvonen P. J., Jalava K. M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996 Jul;60(1):54–61. doi: 10.1016/S0009-9236(96)90167-8. [DOI] [PubMed] [Google Scholar]
  39. Neuvonen P. J., Kantola T., Kivistö K. T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998 Mar;63(3):332–341. doi: 10.1016/S0009-9236(98)90165-5. [DOI] [PubMed] [Google Scholar]
  40. Ozdemir V., Fourie J., Busto U., Naranjo C. A. Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Clin Pharmacokinet. 1996 Nov;31(5):372–385. doi: 10.2165/00003088-199631050-00004. [DOI] [PubMed] [Google Scholar]
  41. Pedersen T. R., Berg K., Cook T. J., Faergeman O., Haghfelt T., Kjekshus J., Miettinen T., Musliner T. A., Olsson A. G., Pyörälä K. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996 Oct 14;156(18):2085–2092. [PubMed] [Google Scholar]
  42. Pierce L. R., Wysowski D. K., Gross T. P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990 Jul 4;264(1):71–75. [PubMed] [Google Scholar]
  43. Pounder D. J., Hartley A. K., Watmough P. J. Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. Am J Forensic Med Pathol. 1994 Sep;15(3):231–235. doi: 10.1097/00000433-199409000-00010. [DOI] [PubMed] [Google Scholar]
  44. Rendic S., Di Carlo F. J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997 Feb-May;29(1-2):413–580. doi: 10.3109/03602539709037591. [DOI] [PubMed] [Google Scholar]
  45. Scalvini T., Marocolo D., Cerudelli B., Sleiman I., Balestrieri G. P., Giustina G. Pravastatin-associated myopathy. Report of a case. Recenti Prog Med. 1995 May;86(5):198–200. [PubMed] [Google Scholar]
  46. Smith P. F., Eydelloth R. S., Grossman S. J., Stubbs R. J., Schwartz M. S., Germershausen J. I., Vyas K. P., Kari P. H., MacDonald J. S. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther. 1991 Jun;257(3):1225–1235. [PubMed] [Google Scholar]
  47. Spach D. H., Bauwens J. E., Clark C. D., Burke W. G. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 1991 Feb;154(2):213–215. [PMC free article] [PubMed] [Google Scholar]
  48. Spatzenegger M., Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev. 1995;27(3):397–417. doi: 10.3109/03602539508998329. [DOI] [PubMed] [Google Scholar]
  49. Spence J. D., Munoz C. E., Hendricks L., Latchinian L., Khouri H. E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995 Jul 13;76(2):80A–83A. doi: 10.1016/s0002-9149(05)80024-4. [DOI] [PubMed] [Google Scholar]
  50. Tal A., Rajeshawari M., Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J. 1997 May;90(5):546–547. doi: 10.1097/00007611-199705000-00018. [DOI] [PubMed] [Google Scholar]
  51. Tobert J. A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):28J–34J. doi: 10.1016/0002-9149(88)90004-5. [DOI] [PubMed] [Google Scholar]
  52. Transon C., Leemann T., Vogt N., Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther. 1995 Oct;58(4):412–417. doi: 10.1016/0009-9236(95)90054-3. [DOI] [PubMed] [Google Scholar]
  53. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645. doi: 10.1111/j.1365-2125.1989.tb03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. van Puijenbroek E. P., Du Buf-Vereijken P. W., Spooren P. F., van Doormaal J. J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996 Dec;240(6):403–404. doi: 10.1046/j.1365-2796.1996.48879000.x. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES